![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/09\/5353-new20logo-01-1.png\")
<\/p>\n<\/p>\n
DelveInsight’s <\/span>Vasomotor Symptoms (Hot Flashes\/Night Sweats) market report<\/strong><\/a> offers comprehensive coverage of the current treatment practices, emerging drugs for Hot flashes\/Night sweats and their market share of the individual therapies, current and forecasted Vasomotor symptoms market size from 2018 to 2030 segmented into <\/span>7MM <\/span>(<\/span>the United States, EU5 (Germany, Spain, Italy, France, and the UK), and Japan).<\/span><\/p>\n Some of the Key Findings from the <\/strong>Vasomotor Symptoms Market Report<\/strong><\/a><\/p>\n For a better understanding of the disease, request a sample @ <\/span>Vasomotor Symptoms Market Research<\/strong><\/a><\/p>\n The Vasomotor Symptoms market report<\/strong><\/a> also discusses current Vasomotor Symptoms treatment practices\/algorithms, Vasomotor Symptoms market drivers, Vasomotor Symptoms market barriers, and unmet medical needs in order to curate the best opportunities. It evaluates the Vasomotor Symptoms market’s underlying potential.<\/span><\/p>\n Vasomotor Symptoms: Overview<\/strong><\/p>\n Vasomotor Symptoms are the most commonly reported menopausal symptoms. These symptoms, also known as hot flashes, are characterized by a sudden increase in blood flow, often to the face, neck, and chest, which causes extreme heat and profuse sweating. VMS is a type of temperature dysfunction caused by changes in gonadal hormones. Core body temperature (CBT) normally stays within a narrow range, oscillating with daily circadian rhythms.<\/span><\/p>\n Vasomotor Symptoms Epidemiology Segmentation<\/strong><\/p>\n The Vasomotor Symptoms report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:<\/span><\/p>\n Get the complete epidemiology analysis @ <\/span>Vasomotor Symptoms Associated with Menopause<\/strong><\/a><\/p>\n Vasomotor Symptoms Treatment Landscape<\/strong><\/p>\n There are two types of treatment available for Vasomotor Symptoms- Hormonal Therapies and Non-Hormonal Therapies. <\/span>Premarin (Pfizer), Menest (Pfizer), Alora (Allergan), Climara Pro (Bayer Healthcare), MINIVELLE (Noven Therapeutics), Evamist (Perrigo Pharma), Elestrin (DPT Laboratories), and Bijuva (TherapeuticsMD)<\/strong> are some of the FDA approved Hormonal Therapies for the treatment of Vasomotor Symptoms.<\/span><\/p>\n The Non-Hormonal therapies used for Vasomotor Symptoms treatment include <\/span>antidepressants, gabapentin, and clonidine. Brisdelle <\/strong>is the first and only non-hormonal antidepressant approved for the treatment of Vasomotor Symptoms.<\/span><\/p>\n Vasomotor Symptoms Market<\/strong><\/a><\/p>\n Vasomotor Symptoms Pipeline Therapies and Key Companies <\/strong><\/p>\n For more information on the pipeline therapies and companies, visit <\/span>Vasomotor Symptoms Treatment Drugs<\/strong><\/a><\/p>\n Vasomotor Symptoms Market Drivers<\/strong><\/p>\n Vasomotor Symptoms Market Barriers<\/strong><\/p>\n Scope for the Report<\/strong><\/a><\/p>\n Coverage: <\/strong>7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)<\/span><\/p>\n Study Period: <\/strong>2018-30<\/span><\/p>\n Vasomotor Symptoms Key Companies: <\/strong>Mithra Pharmaceuticals, Astellas Pharma, Bayer, Fervent Pharmaceuticals<\/span>, among others.<\/span> <\/strong><\/p>\n Vasomotor Symptoms Key Pipeline Therapies: <\/strong>Donesta, Fezolinetant, Elinzanetant, FP-101<\/span>,<\/span> and others.<\/span><\/p>\n Vasomotor Symptoms Segmentation: <\/strong>By Geography, Vasomotor Symptoms drugs<\/span><\/p>\n Analysis: <\/strong>Comparative and conjoint analysis of <\/span> Vasomotor Symptoms<\/span> emerging therapies<\/span><\/p>\n Tools Used: <\/strong>SWOT Analysis<\/span><\/p>\n Case Studies<\/strong><\/p>\n KOL’s Views<\/strong><\/p>\n Analyst’s Views<\/strong><\/p>\n Table of Contents<\/strong><\/p>\n Know more about report offerings @ <\/span>Vasomotor Symptoms Market Outlook<\/strong><\/a><\/p>\n Related Reports<\/strong><\/p>\n![\"Vasomotor-Symptoms-Market-Insights\"](\"https:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/Vasomotor-Symptoms-Market-Insights.jpg?1631506355276\")
<\/span><\/p>\n\n
\n
\n
\n
\n
\n
\n\n
\n 1.<\/td>\n Key Insights<\/span><\/td>\n<\/tr>\n \n 2.<\/td>\n Vasomotor Symptoms: Market Overview at a Glance<\/span><\/td>\n<\/tr>\n \n 3.<\/td>\n Executive summary<\/span><\/td>\n<\/tr>\n \n 4.<\/td>\n Organizations<\/span><\/td>\n<\/tr>\n \n 5.<\/td>\n Vasomotor Symptoms Epidemiology and Market Methodology<\/span><\/td>\n<\/tr>\n \n 6.<\/td>\n Vasomotor Symptoms (VMS) associated with menopause: Disease Background and Overview<\/span><\/td>\n<\/tr>\n \n 7.<\/td>\n Vasomotor Symptoms Epidemiology and Patient Population<\/span><\/td>\n<\/tr>\n \n 8.<\/td>\n Total Prevalent cases of Vasomotor Symptoms in Post-menopause in 7MM<\/span><\/td>\n<\/tr>\n \n 9.<\/td>\n Country Wise-Epidemiology of Hot Flashes Associated with Post-menopause<\/span><\/td>\n<\/tr>\n \n 10.<\/td>\n Vasomotor Symptoms Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/td>\n<\/tr>\n \n 11.<\/td>\n Vasomotor Symptoms Unmet Needs<\/span><\/td>\n<\/tr>\n \n 12.<\/td>\n Vasomotor Symptoms Marketed drugs by class<\/span><\/td>\n<\/tr>\n \n 13.<\/td>\n Vasomotor Symptoms Emerging Therapies<\/span><\/td>\n<\/tr>\n \n 14.<\/td>\n Vasomotor Symptoms: 7 Major Market Analysis<\/span><\/td>\n<\/tr>\n \n 15.<\/td>\n Vasomotor Symptoms Seven Major Market Outlook<\/span><\/td>\n<\/tr>\n \n 16.<\/td>\n Vasomotor Symptoms Market Drivers<\/span><\/td>\n<\/tr>\n \n 17.<\/td>\n Vasomotor Symptoms Market Barriers<\/span><\/td>\n<\/tr>\n \n 18.<\/td>\n SWOT<\/span><\/td>\n<\/tr>\n \n 19.<\/td>\n Case Studies<\/span><\/td>\n<\/tr>\n \n 20.<\/td>\n KOL Views<\/span><\/td>\n<\/tr>\n \n 21.<\/td>\n Appendix<\/span><\/td>\n<\/tr>\n \n 22.<\/td>\n DelveInsight Capabilities<\/span><\/td>\n<\/tr>\n \n 23.<\/td>\n Disclaimer<\/span><\/td>\n<\/tr>\n \n 24.<\/td>\n About DelveInsight<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n